<DOC>
	<DOC>NCT02745080</DOC>
	<brief_summary>The purpose of this study is to compare the safety and efficacy of secukinumab monotherapy and adalimumab monotherapy in patients with active psoriatic arthritis who are naïve to biologic therapy and are intolerant or having inadequate response to conventional DMARDs</brief_summary>
	<brief_title>Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis of PsA classified by CASPAR; Rheumatoid factor and antiCCP antibodies negative; diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥2cm diameter or nail changes consistent with psoriasis or documented history of plaque psoriasis; inadequate control of symptoms with NSAIDs; inadequate control of symptoms with a conventional DMARD. Pregnant or nursing women, evidence of ongoing infectious or malignant process; previous exposure to any biologic drug for Psoriatic Arthritis or Psoriasis; subjects taking high potency opioid analgesics; ongoing use of prohibited psoriasis treatments / medications; previous treatment with any celldepleting therapies including but not limited to antiCD20, investigational agents. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>secukinumab</keyword>
	<keyword>adalimumab</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>CASPAR</keyword>
</DOC>